CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
March 15th 2024
Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population.
Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia
April 23rd 2021Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.